ZPDH:XETRA:XETRA-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 41.26

Change

-0.52 (-1.24)%

Market Cap

USD 0.40B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.01 (-0.02%)

USD 420.85B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.08%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.09%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.02 (-0.07%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.09 (+0.35%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

-0.13 (-0.29%)

USD 102.32B
8R80:XETRA Amundi Index Solutions - Amund..

+0.18 (+0.13%)

USD 102.11B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.06 (-0.12%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.50 (-0.50%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-1.84 (-0.32%)

USD 80.38B

ETFs Containing ZPDH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.15% 61% D- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.15% 62% D 64% D
Trailing 12 Months  
Capital Gain 16.47% 48% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.47% 49% F 53% F
Trailing 5 Years  
Capital Gain 70.81% 84% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.81% 84% B 84% B
Average Annual (5 Year Horizon)  
Capital Gain 12.20% 77% C+ 75% C
Dividend Return 12.20% 76% C+ 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.85% 57% F 66% D+
Risk Adjusted Return 112.45% 99% N/A 99% N/A
Market Capitalization 0.40B 61% D- 53% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike